Valneva SE, a specialty vaccine company, has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years. The EC approved the APA earlier this month.   Under the agreement following final review of the volumes by each of the EU Member States, Valneva expects to deliver 24.3 million doses during the second and third quarters of 2022, subject to approval of VLA2001 by the EMA....